Join the Everolimus group to help and get support from people like you.
Everolimus News
Survival Improved With Everolimus in High-Risk Clear Cell Renal Cancer
MONDAY, Oct. 23, 2023 – For patients with clear cell renal cell carcinoma (RCC) at very high risk for recurrence, adjuvant everolimus is associated with significantly improved recurrence-free...
Five-Year Composite Outcome Similar for TiNO-Coated Stent, Everolimus-Eluting Stents
TUESDAY, May 30, 2023 – For patients with acute coronary syndrome (ACS), titanium-nitride-oxide (TiNO)-coated stents do not improve long-term outcomes in terms of a composite outcome over...
Long-Term Outcomes Similar for Bioresorbable Vascular Scaffolds Versus Metal Stents
WEDNESDAY, May 24, 2023 – For patients undergoing percutaneous coronary intervention, first-generation bioresorbable vascular scaffolds (BVS) seem to be as safe as cobalt chromium everolimus-eluting...
FDA Approves Afinitor Disperz (everolimus) for Tuberous Sclerosis Complex-Associated Partial-Onset Seizures
April 11, 2018 – On April 10, 2018, the Food and Drug Administration approved everolimus tablets for oral suspension (Afinitor Disperz, Novartis Pharmaceuticals Corp.) for the adjunctive treatment...
FDA Approves Afinitor (everolimus) for Progressive, Nonfunctional Gastrointestinal and Lung Neuroendocrine Tumors (NET)
EAST HANOVER, N.J., Feb. 26, 2016 Novartis today announced that the United States Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of adult patients with...
FDA Approves Afinitor Disperz - First Drug Formulated for Children with Rare Brain Tumor
The U.S. Food and Drug Administration today approved Afinitor Disperz (everolimus tablets for oral suspension), a new pediatric dosage form of the anti-cancer drug Afinitor (everolimus) used to treat...
FDA Approves Afinitor for Advanced Breast Cancer
July 20, 2012 – The U.S. Food and Drug Administration today approved Afinitor (everolimus) for use in combination with Aromasin (exemestane) to treat certain postmenopausal women with advanced...
Novartis drug Afinitor approved by FDA as first medication to treat patients with non-cancerous kidney tumors associated with TSC
-- Kidney tumors affect up to 80% of patients with tuberous sclerosis complex (TSC) and growing tumors may lead to unpredictable life-threatening complications(1) – Prior to the approval of...
Novartis Gains FDA Approval for Afinitor As First New Treatment in Nearly Three Decades for Patients With Advanced Pancreatic NET
Basel, May 5, 2011 - Novartis announced today that the US Food and Drug Administration (FDA) approved Afinitor (everolimus) tablets for the treatment of progressive neuroendocrine tumors of...
FDA Approves New Indication for Afinitor
SILVER SPRING, Md., Nov. 1, 2010 /PRNewswire-USNewswire/ – The U.S. Food and Drug Administration approved the cancer drug Afinitor (everolimus) on Friday to treat patients with subependymal giant...
Ask a question
To post your own question to this support group, sign in or create an account.
Further information
Related condition support groups
Breast Cancer, Renal Cell Carcinoma